APA (7th ed.) Citation

B, S., A, B., RB, W., KA, P., AW, A., KB, G., . . . D, T. (2024). Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). Journal of the European Academy of Dermatology and Venereology : JEADV, 38(8), 1543. https://doi.org/10.1111/jdv.19925

Chicago Style (17th ed.) Citation

B, Strober, et al. "Deucravacitinib in Moderate-to-severe Plaque Psoriasis: Pooled Safety and Tolerability over 52 weeks from Two Phase 3 Trials (POETYK PSO-1 and PSO-2)." Journal of the European Academy of Dermatology and Venereology : JEADV 38, no. 8 (2024): 1543. https://doi.org/10.1111/jdv.19925.

MLA (9th ed.) Citation

B, Strober, et al. "Deucravacitinib in Moderate-to-severe Plaque Psoriasis: Pooled Safety and Tolerability over 52 weeks from Two Phase 3 Trials (POETYK PSO-1 and PSO-2)." Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 38, no. 8, 2024, p. 1543, https://doi.org/10.1111/jdv.19925.